The authors appreciate that Shujie Huang et al., along with Xiaoling Xu et al., highlighted valuable insights from the HARMONi-6 trial.[1] This commentary is in response to the authors' comments on the associations of PD-L1, treatment intensity, and outcomes in squamous NSCLC.[1] The HARMONi-6 study demonstrated a significant improvement in progression-free survival (PFS) with ivonescimab in combination with first-line chemotherapy versus pembrolizumab.[1] Previous research has confirmed that ivonescimab significantly improved PFS compared with pembrolizumab as a first-line treatment.[1] The authors respond to these suggestions in the context of their original article.[1]